Peptide Antibiotics, API

COOPERATION OPTIONS

LICENSE

FROM 150 MILLION RUR

RESEARCH PARTNERSHIP

FROM 50 MILLION RUR

more detail

ABOUT THE PROJECT

PEPTIDE ANTIBIOTICS, API

ANTIBIOTICS, BASED ON NATURAL MOLECULES THAT PLAY A KEY ROLE IN PROTECTING ORGANISMS FROM INFECTION.

Peptide antibiotics, based on natural molecules, that play a key role in protecting organisms from infection - antimicrobial peptides (AMPs) - are being developed to solve the problems of multi- and cross-resistance of socially important bacterial pathogens. 

The key objective of the development is to minimize the cytotoxic effects of these compounds. To solve this problem, we work to obtain mutant analogues of a number of known and novel natural AMPs, that have high therapeutic value and selectivity of action against a wide range of bacteria. Antibacterial drugs with a broad spectrum of activity, both for external and systemic use, are developed on the basis of the obtained analogues.  

STAGE OF DEVELOPMENT

PEPTIDE ANTIBIOTICS, API

COOPERATION OPTIONS

LICENSE

FROM 150 MILLION RUR

RESEARCH PARTNERSHIP

FROM 50 MILLION RUR

more detail

ABOUT THE PROJECT

PEPTIDE ANTIBIOTICS, API

ANTIBIOTICS, BASED ON NATURAL MOLECULES THAT PLAY A KEY ROLE IN PROTECTING ORGANISMS FROM INFECTION.

Peptide antibiotics, based on natural molecules, that play a key role in protecting organisms from infection - antimicrobial peptides (AMPs) - are being developed to solve the problems of multi- and cross-resistance of socially important bacterial pathogens. 

The key objective of the development is to minimize the cytotoxic effects of these compounds. To solve this problem, we work to obtain mutant analogues of a number of known and novel natural AMPs, that have high therapeutic value and selectivity of action against a wide range of bacteria. Antibacterial drugs with a broad spectrum of activity, both for external and systemic use, are developed on the basis of the obtained analogues.  

STAGE OF DEVELOPMENT

STAGE OF DEVELOPMENT
& RESULTS OF INTELLECTUAL ACTIVITY STATUS


APPLICATION

Creation of new highly effective and safe drugs with antibacterial action for the treatment of hospital-acquired multidrug-resistant infections.

BENEFITS

A fundamentally new mechanism of antibacterial action acts both on the bacterial membrane and on intracellular targets found. This results in a low probability of resistant bacterial strains when potentially used in medicine, as well as an opportunity to minimize the global problem of antibiotic resistance
THE ABSENCE OF BACTERIAL CROSS-RESISTANCE EFFECTS AGAINST MANY AMPS MAKES IT POSSIBLE TO CREATE A POOL OF RESERVE PEPTIDE DRUGS FOR THE THERAPY OF INFECTIONS, RESISTANT TO ALL ANTIBIOTICS USED IN CLINICAL PRACTICE
SYNERGISTIC ANTIBACTERIAL ACTION WITH KNOWN ANTIBIOTICS
LOW IMMUNOGENICITY AND ABILITY TO BIND ENDOTOXINS 

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - starting at RUB 150 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 470 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:

• Preclinical studies
Starting at 50 million RUR

• Clinical trials, phase 1
Starting at 100 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Preclinical studies
Starting at 50 million RUR

• Clinical trials, phase 1
Starting at 100 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

• Start manufacturing
Starting at 20 million RUR

• Promotion activities
Starting at 50 million RUR

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

HEAD OF THE PROJECT

TATIANA OVCHINNIKOVA

Dr. of Sc.
Professor

Awards: Medal of the Order of Merit for the Fatherland, II degree.

Deputy Head of the NTI Center IBH RAS (Director of Scientific and Educational Activities Department)

 


PUBLICATIONS

Scientists will create drugs against antibiotic-resistant bacteria from worm peptides

A new generation of antibiotics will be developed at the NTIС of the Institute of Bioorganic Chemistry

By 2021, the CNTI IBCh RAS will develop prototypes of new antibiotics

CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more
Report abuse